Clinical Trial News and Research

RSS

New hybrid OR at Loyola equipped with advanced fluoroscopy equipment

Loyola University Medical Center has opened a hybrid operating room that combines the imaging capabilities of a cardiac catheterization lab with the sterile environment of a conventional operating room (OR).

23 May 2011

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Sangamo BioSciences, Inc. announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

23 May 2011

Stanford University develops stress-shielding device to reduce surgical scarring

Researchers at Stanford University have developed a special wound dressing that they report was able to significantly reduce scar tissue caused by incisions.

23 May 2011

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Although chemotherapy is used to kill cancer cells, it can also have a strong toxic effect on normal cells such as bone marrow and blood cells, often limiting the ability to use and manage the chemotherapy treatment.

21 May 2011

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

A pooled analysis of the global RESOLUTE clinical program presented today during a late-breaking clinical trials session at EuroPCR demonstrated the strong safety record of the Resolute drug-eluting stent (DES) from Medtronic, Inc., across a wide variety of patient and lesion types.

From Medtronic 21 May 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.

20 May 2011

Accovion establishes new subsidiary in the UK

As a European full-service Clinical Research Organization, Accovion supports local and global projects of all types and phases for the Pharmaceutical, Biotechnology and Medical Device industries.

20 May 2011

RTOG reports on largest trial for newly diagnosed glioblastoma

RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.

19 May 2011

Medical food resolves metabolic syndrome and cardiovascular risk factors

Researchers at the University of Florida and Metagenics Inc. today announced that a program consisting of a breakthrough medical food combined with a low-glycemic, Mediterranean-style diet is almost twice as effective as one of the best diets alone for lowering risk factors for cardiovascular disease, the leading cause of death in the U.S.

19 May 2011

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.

19 May 2011

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.

19 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.

19 May 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen Corporation announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy.

19 May 2011

Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs

Omeros Corporation today announced that it is advancing two of its product candidates from its PharmacoSurgery platform – OMS103HP for arthroscopic meniscectomy and OMS302 for intra-ocular lens replacement surgery – into Phase 3 clinical development programs.

19 May 2011

AVAC calls on donors, policy makers to strengthen support for AIDS vaccine research

This year HIV Vaccine Awareness Day comes at the dawn of a true prevention revolution that could finally turn the tide of the AIDS epidemic. AIDS vaccine research is a critical part of that revolution and on this day AVAC calls on donors, policy makers and others to strengthen support for AIDS vaccine research.

19 May 2011

TissueGene commences enrollment in TG-C Phase II trial for severe knee osteoarthritis

TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.

19 May 2011

Clinical Trial News and Research

New hybrid OR at Loyola equipped with advanced fluoroscopy equipment

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Stanford University develops stress-shielding device to reduce surgical scarring

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Accovion establishes new subsidiary in the UK

RTOG reports on largest trial for newly diagnosed glioblastoma

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Medical food resolves metabolic syndrome and cardiovascular risk factors

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs

AVAC calls on donors, policy makers to strengthen support for AIDS vaccine research

TissueGene commences enrollment in TG-C Phase II trial for severe knee osteoarthritis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News